New aspects in the management of exudative age-related macular degeneration - Current position of the Retinological Society, the German Ophthalmology Society and theProfessional Union of Ophthalmologists inGermany;Neue Aspekte in der Therapie der neovaskulären altersabhängigen Makuladegeneration - Aktuelle Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands e. V.

Klinische Monatsblatter fur Augenheilkunde

Volumn 226, Issue 5, 2009, Pages 388-395

[No Author Info available]

Author keywords

Age related macular degeneration; Preferred practice pattern

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; PROTEIN KINASE INHIBITOR; RANIBIZUMAB; SMALL INTERFERING RNA; VERTEPORFIN;

CLINICAL PRACTICE; GERMANY; HUMAN; MEDICAL SOCIETY; OPHTHALMOLOGY; PHOTODYNAMIC THERAPY; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; ARTICLE; EXUDATE; PRACTICE GUIDELINE; RETINA MACULA DEGENERATION; STANDARD;

EXUDATES AND TRANSUDATES; GERMANY; HUMANS; MACULAR DEGENERATION; OPHTHALMOLOGY; PRACTICE GUIDELINES AS TOPIC;

EID: 68849103196     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1109432     Document Type: Review

References (51)

1. Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands zu aktuellen therapeutischen Moglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration. Klin Monatsbl Augenheilkd 2007 224 559-566
2. Aktuelle therapeutische Möglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration. Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands zu aktuellen therapeutischen Moglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration. Ophthalmologe 2007 104 628-634
3. Stellungnahme zu aktuellen therapeutischen Möglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration. Klin Monatsbl Augenheilkd 2006 223 271-278
4. Antoszyk A N., Tuomi L, Chung C Y. et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 2008 145 862-874
5. Schmidt-Erfurth U, Wolf S. Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration. Br J Ophthalmol 2008 92 1628-1635
6. Singerman L J., Masonson H, Patel M et al. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol 2008 92 1606-1611
7. Gragoudas E S., Adamis A P., Cunningham E T. et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004 351 2805-2816
8. Chakravarthy U, Adamis A P., Cunningham E T. et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006 113 1508-1521
9. Farah S E. Treatment of neovascular age-related macular degeneration with pegaptanib and boosting with bevacizumab or ranibizumab as needed. Ophthalmic Surg Lasers Imaging 2008 39 294-298
10. Hughes M S., Sang D N. Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2006 37 446-454
11. Brown D M., Kaiser P K., Michels M Jr et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006 355 1432-1444
12. Rosenfeld P J., Brown D M., Heier J S. et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006 355 1419-1431
13. Fachinformation Lucentis® (Stand August 2008). Rote Liste GmbH Novartis Pharma GmbH 2008
14. Regillo C D., Brown D M., Abraham P et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008 145 239-248
15. Lommatzsch A P., Heimes B, Gutfleisch M et al. Die Therapie der vaskularisierten serosen Pigmentepithelabhebung bei AMD Beobachtungen nach Wechsel des intravitrealen Medikamentes bei Therapieversagen. Klin Monatsbl Augenheilkd 2008 225 874-879
16. Alexander S L., Linde-Zwirble W T., Werther W et al. Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients. Ophthalmology 2007 114 2174-2178
17. Dafer R M., Schneck M, Friberg T R. et al. Intravitreal ranibizumab and bevacizumab: a review of risk. Semin Ophthalmol 2007 22 201-204
18. Investigator Notification for ranibizumab: Lucentis Meta-Analysis. Novartis NSO Basel CH 2008
19. Rote-Hand-Brief: Avastin Bevacizumab. Roche Pharma AG 2009 http://www.pei.de/SharedDocs/Downloads/fachkreise/rhb/09 02 11-rhb-avastin, templateId = raw,property = publicationFile.pdf/09 02 11-rhb-avastin.pdf
20. Wild C, Adlbrecht C. Avastina® bei Altersbedingter Makuladegeneration. Analyse der Sicherheit und Nebenwirkungen. 2007 http://eprints.hta.lbg.ac.at/718/1/Rapid-Assessment-002.pdf
21. Schouten J S., La Heij E C., Webers C A. et al. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2009 247 1-11
22. Ip M S., Scott I U., Brown G C. et al. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology 2008 115 1837-1846
23. Gamulescu M A., Framme C, Sachs H. RPE-rip after intravitreal bevacizumab (Avastin) treatment for vascularised PED secondary to AMD. Graefes Arch Clin Exp Ophthalmol 2007 245 1037-1040
24. Kook D, Wolf A, Neubauer A S. et al. Retinale Pigmentepithelrisse nach intravitrealem Bevacizumab bei AMD. Häufigkeit und Verlauf. Ophthalmologe 2008 105 158-164
25. Weinberger A W., Thiel M, Mohammadi B et al. Retinal pigment epithelium tears after intravitreal bevacizumab in pigment epithelium detachment. Am J Ophthalmol 2007 144 294-296
26. Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). http://www.med.upenn.edu/cpob/studies/CATT.shtml
27. Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab (VIBERA). http://www.clinicaltrials.gov/ct2/show/NCT00559715
28. Prävention des Sehverlustes bei Patienten mit altersabhängiger Makuladegeneration durch intravitreale Injektion von Bevacizumab und Ranibizumab. http://www.pharmakologie-bremen.de/index.php/klinische-forschung/ vibera
29. A randomised controlled trial of alternative treatments to inhibit VEGF in age-related choroidal neovascularisation. http://www.controlled-trials.com/ ISRCTN92166560
30. Fintak D R., Shah G K., Blinder K J. et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008 28 1395-1399
31. Angulo Bocco M C., Glacet-Bernard A, Zourdani A et al. Injection intravitŕenne: ́valuation ŕtrospective de la technique et des complications dune serie de 2028 injections. JFr Ophtalmol 2008 31 693-698
32. Wu L, Martinez-Castellanos M A., Quiroz-Mercado H et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin(R)): results ofthe Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008 246 81-87
33. Chappelow A V., Kaiser P K. Neovascular age-related macular degeneration: potential therapies. Drugs 2008 68 1029-1036
34. Nguyen Q D., Shah S M., Hafiz G et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006 113 1522 e1521-1522 e1514
35. VEGF Trap-Eye in Wet AMD CLEAR-IT 2: Summary of One-Year Key Results. 2008 http://library.corporate-ir.net/library/11/119/119 576/items/309 061/Final2-0508-Week52-Website-Slides-9 26 08.pdf
36. Kleinman M E., Yamada K, Takeda A et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008 452 591-597
37. Dejneka N S., Wan S, Bond O S. et al. Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes. Mol Vis 2008 14 997-1005
38. OPKO Health Announces Completion of Enrollment for Its Phase III Clinical Trial of Bevasiranib for Treatment of AMD. 2008 http://investor.opko.com/ releasedetail.cfm?ReleaseID=352313
39. Heimes B, Lommatzsch A, Zeimer M et al. Foveal RPE autofluorescence as a prognostic factor for anti-VEGF therapy in exudative AMD. Graefes Arch Clin Exp Ophthalmol 2008 246 1229-1234
40. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol 1991 109 1109-1114
41. Colquitt J L., Jones J, Tan S C. et al. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess 2008 12 iii-iv, ix-201
42. NICE technology appraisal guidance 155. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration. 2008 www.nice.org.uk/TA155
43. Schmidt-Erfurth U M., Richard G, Augustin A et al. Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand 2007 85 486-494
44. Empfehlung der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands für die Durchführung von intravitrealen Injektionen (IVI). 2007 http://www.dog.org/publikationen/DOG-Empfehlung-Intravitreale- Injektionen.pdf
45. Aiello L P., Brucker A J., Chang S et al. Evolving guidelines for intravitreous injections. Retina 2004 24 S3-19
46. Scott I U., Flynn H W. Reducing the risk of endophthalmitis following intravitreal injections. Retina 2007 27 10-12
47. Meyer C H., Mennel S, Eter N. Endophthalmitisrate mit und ohne topische postoperative Antibiotikagabe nach intravitrealer Avastin-injektion. Ophthalmologe 2007 104 952-957
48. Hart D. Off-Label-Use von Arzneimitteln: Hintergründe und Lösungsansätze eines vielschichtigen Problems. Arzneimittelbrief 2008 42 81-96
49. Dierks C, Nitz G. Rechtsfortbildung dank Lucentis? Gesellschaftspolitische Kommentare 2008 11 3-7
50. Hart D. Arzthaftung und off label use. Information, Standard und Zulassung. Medizinrecht heute: Erfahrungen, Analysen, Entwicklungen Festschrift: 10 Jahre Arbeitsgemeinschaft Medizinrecht im DAW Deutscher Anwaltverlag 2008 173-190
51. Francke R, Hart D. Off label use Arzneimittelrechtliche, haftungsrechtliche, berufsrechtliche und sozialrechtliche Fragen. Die Sozialgerichtsbarkeit 2003 50 653-664